This trial is testing a new drug, APX005M, to see if it is safe and effective when used with nivolumab and ipilimumab to treat advanced melanoma and renal cell carcinoma.
- Advanced Melanoma
- Kidney Cancer
2 Primary · 2 Secondary · Reporting Duration: Up to 2 years
Side Effects for
2 Treatment Groups
Dose Level 1 (DL1)
1 of 2
Dose Level 2 (DL2)
1 of 2
36 Total Participants · 2 Treatment Groups
Primary Treatment: APX005M · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18+ · All Participants · 15 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What pathologies is APX005M designed to address?
"APX005M is frequently administered to treat anti-angiogenic therapy, but it can also be beneficial for patients with unresectable melanoma, squamous cell carcinoma, and other malignant neoplasms." - Anonymous Online Contributor
To what extent is the current clinical trial being utilized by participants?
"Affirmative. According to the information provided on clinicaltrials.gov, this investigation is actively recruiting participants with its first post dated September 14th 2020 and most recent update from November 22nd 2022. In total, 36 individuals are needed at 2 medical facilities for enrollment in this examination." - Anonymous Online Contributor
What have other researchers discovered through investigations of APX005M?
"Currently, 769 research studies for APX005M are being conducted; 86 of those live clinical trials fall within the Phase 3 category. The majority of these investigations take place in Pittsburgh, Pennsylvania though there are 42779 other locations that feature similar experiments with this medication." - Anonymous Online Contributor
Are there any open slots available for participants in this experiment?
"Indeed, the clinicaltrials.gov website shows that this trial is currently inviting participants to join. The investigation was first advertised on September 14th 2020 and has since been updated on November 22nd 2022. Across two sites, a total of 36 patients are needed for inclusion in the study." - Anonymous Online Contributor
Is APX005M a reliable and secure therapeutic option?
"The lack of prior clinical data surrounding APX005M's safety and efficacy warrants a score of 1." - Anonymous Online Contributor